Trial Profile
A Phase 2a Study to Evaluate the Clinical Effect, Pharmacokinetics, Safety and Tolerability of Topically Applied Umeclidinium in Subjects With Primary Palmar Hyperhidrosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary)
- Indications Hyperhidrosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Stiefel Laboratories
- 20 Dec 2016 Status changed from active, no longer recruiting to completed.
- 28 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 28 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Dec 2016.